Latest Financial Markets News

Macquarie Bank Limited reported an 18% rise in net profit for FY2025, driven by growth in its retail banking segment despite margin pressures, while its commodities business faced subdued markets. The bank maintained strong capital ratios and advanced its risk and technology frameworks amid regulatory scrutiny.

Macquarie Group reported a 5% rise in full-year net profit to A$3.715 billion for FY25, driven by growth across its diversified businesses and a solid capital position. The group’s assets under management reached A$941 billion, supported by strong home loan and deposit growth.

Macquarie Group reported a 5% increase in full-year net profit to A$3.7 billion for FY25, driven by strong second-half growth and robust asset management performance. The company declared a final dividend of A$3.90 per share and extended its share buyback program.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy by executing three CAR-T term sheets and completing technical due diligence, while implementing cost-cutting measures and seeking new capital amid a tough financing environment.

EverGreen Lithium’s 2024 drilling at the Bynoe Project confirms anomalous gold mineralisation but no significant lithium, prompting a strategic pivot to expanded gold and pegmatite exploration in 2025.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Omni Bridgeway reports robust investment performance for FY25, highlighted by record proceeds and a landmark Fund 9 transaction that strengthens its balance sheet and strategic position.

Petratherm Limited has confirmed a significant titanium-rich heavy mineral sands discovery at its Muckanippie Project, with drilling extending mineralisation over 15 square kilometres and a recent $8.1 million placement to accelerate development.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Citigroup Global Markets Australia has announced a partially franked dividend of AUD 2.15 for COH CitiFirst Instalments, with key dates set for March and April 2025.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Fiducian Group Limited reported a robust half-year result for December 2024, with revenue up 14% and net profit after tax rising 26%, underpinning a higher fully franked interim dividend.